LBTSF Stock - Almirall, S.A.
Unlock GoAI Insights for LBTSF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $985.72M | $894.52M | $863.25M | $827.20M | $1.61B |
| Gross Profit | $767.68M | $682.04M | $680.78M | $655.61M | $1.44B |
| Gross Margin | 77.9% | 76.2% | 78.9% | 79.3% | 89.3% |
| Operating Income | $36.09M | $-5,264,000 | $46.87M | $5.75M | $92.30M |
| Net Income | $10.15M | $-38,474,000 | $4.28M | $-40,859,000 | $74.28M |
| Net Margin | 1.0% | -4.3% | 0.5% | -4.9% | 4.6% |
| EPS | $0.04 | $-0.20 | $0.02 | $-0.23 | $0.42 |
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 19th 2022 | Morgan Stanley | Downgrade | Equal Weight | - |
| September 28th 2022 | RBC Capital Mkts | Initiation | Outperform | - |
Earnings History & Surprises
LBTSFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 10, 2025 | — | $0.07 | — | — |
Q3 2025 | Jul 25, 2025 | — | $0.03 | — | — |
Q2 2025 | May 12, 2025 | — | $0.11 | — | — |
Q1 2025 | Feb 24, 2025 | — | $0.01 | — | — |
Q4 2024 | Nov 11, 2024 | — | $-0.04 | — | — |
Q3 2024 | Jul 22, 2024 | — | $0.04 | — | — |
Q2 2024 | May 13, 2024 | — | $0.04 | — | — |
Q1 2024 | Feb 19, 2024 | — | $-0.27 | — | — |
Q3 2023 | Sep 30, 2023 | — | $0.01 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.03 | — | — |
Q1 2023 | Mar 31, 2023 | — | $0.05 | — | — |
Q1 2023 | Feb 20, 2023 | $0.08 | $-0.14 | -271.0% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | — | $-0.09 | — | — |
Q3 2022 | Jul 25, 2022 | $0.05 | $0.04 | -20.0% | ✗ MISS |
Q2 2022 | May 9, 2022 | $0.06 | $0.11 | +83.3% | ✓ BEAT |
Q1 2022 | Feb 21, 2022 | $0.02 | $0.11 | +369.5% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $0.07 | $0.01 | -85.7% | ✗ MISS |
Q3 2021 | Jul 26, 2021 | $0.10 | $0.08 | -20.0% | ✗ MISS |
Q2 2021 | May 10, 2021 | $0.11 | $0.23 | +109.1% | ✓ BEAT |
Q1 2021 | Feb 22, 2021 | $0.10 | $0.10 | 0.0% | = MET |
Latest News
Frequently Asked Questions about LBTSF
What is LBTSF's current stock price?
What is the analyst price target for LBTSF?
What sector is Almirall, S.A. in?
What is LBTSF's market cap?
Does LBTSF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to LBTSF for comparison